Revenue segments as reported by the company.

Product sales

Royalty, contract and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development expenses

Selling, general and administrative

In-process research and development impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Gilead Sciences reports robust earnings, eyes pipeline opportunities for growth

Gilead Sciences delivered strong financial performance in Q4 2022, driven by growth in key product sales. Despite facing challenges in the HIV market for Q1 2023, the company remains focused on leveraging opportunities in its pipeline and strategic investments.

Gilead reports strong Q1 sales, focuses on pipeline growth

Gilead Sciences delivered strong sales driven by key products in Q1 2023.
While facing challenges like lower Veklury sales, Gilead maintains revenue guidance.
The company's strengths lie in its pipeline, successful products, and manufacturing capabilities.
Opportunities in new indications and therapies position Gilead for future growth.

Gilead Sciences reports robust Q2 performance and eyes future growth

Gilead Sciences had a strong quarter with growth in sales and positive pipeline updates.
Trodelvy's performance in different markets and potential Medicare coverage are key highlights.
Challenges include unsuccessful trials and addressing revenue aspirations.
Opportunities lie in expanding BD activities and exploring cell therapy beyond oncology.

Gilead Sciences reports robust Q3 performance amidst market challenges

Gilead Sciences demonstrated strong performance in Q3 2023, driven by growth in base business, oncology, and HIV segments.
While facing challenges such as declining Veklury sales and barriers to CART therapy uptake, Gilead is actively addressing opportunities for growth and market expansion.
The company's strengths lie in robust product sales, particularly in Biktarvy and Trodelvy, with a focus on innovation and strategic positioning in key therapeutic areas.
Overall, Gilead's performance reflects resilience and strategic planning amidst evolving market dynamics and competitive landscapes.

Gilead Sciences reports strong 2023 performance, eyes transformative therapies

Gilead Sciences showcased solid performance in 2023 with notable growth in key product sales areas, despite facing challenges in certain clinical trials. The company's strengths lie in its diverse portfolio, pipeline innovation, and commitment to delivering transformative therapies. With a focus on addressing HIV, oncology, and inflammation, Gilead is well-positioned for future growth and success.

Gilead Sciences reports robust Q1 performance and eyes future growth

Gilead Sciences delivered strong Q1 results driven by oncology and HIV product sales.
Challenges include IP R&D charge from Sema Bay acquisition and competitive market dynamics.
Opportunities lie in expanding cell therapy leadership, advancing HIV pipeline, and upcoming pipeline updates.
Overall, Gilead remains focused on growth through innovation and strategic portfolio advancements.

Gilead Sciences reports robust Q3 performance and eyes market expansion

Gilead Sciences' Q3 performance reflects strong revenue growth and market leadership in key segments, supported by successful product launches and strategic initiatives.
The company's focus on innovation, patient-centric approaches, and market expansion bodes well for future growth and competitive positioning.
While challenges in maintaining growth and managing expenses exist, Gilead's proactive stance on addressing market needs and leveraging opportunities positions it for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shares of Gilead Science Inc. (GILD) rally on media reports that severe coronavirus patients were responding positively to the company's experimental treatment, remdesivir.

Gilead Brings Likely Coronavirus Cure, Pharma Rallies on R&D

Remdesivir was one of the first medicines identified as a contender to treat Covid-19 given it showed promise in the past in treating SARS and MERS.

Investors should be cautious on the potential for Gilead's drug Remdesivir, analysts says

Gilead Sciences Inc. (NASDAQ: GILD) started human trials of its prospect antiviral, Remdesivir, recently in critical cases of COVID-19.

Gilead Sciences jumps 16% as severe COVID-19 patients respond to its antiviral drug

STAT Obtained Data Indicates COVID-19 Treatment Potentially Effective

Gilead Sciences Inc's shares surged 16% in after hours trading on Thursday following a media report detailing encouraging partial data from trials of the U.S. company's experimental drug remdesivir in severe COVID-19 patients.

Report says COVID-19 patients respond to Gilead's remdesivir, shares surge

Shares of Gilead Sciences Inc  soared 15% on Thursday after a media report suggested that severe COVID-19 patients were positively responding to the drugmaker's experimental treatment remdesivir.

Gilead surges after report suggests COVID-19 patients responding to remdesivir

While the COVID-19 pandemic wrecked the stock market and the economy, the recent rally in the stock market has been at a time when the economic news is only getting worse and as coronavirus news seems to be getting a bit less negative than in prior weeks.

Stock Futures Surge as Gilead’s Remdesivir Could Be COVID-19 Top Treatment Candidate

Shares of Gilead Sciences, Inc. (NASDAQ: GILD) gained more than 15% after Thursday's market close and the encouraging report from STAT is "good news" although anecdotal, CNBC's Guy Adami said.

Gilead's Encouraging Remdesivir Data: Rapid Reaction On The Stock

Its COVID-19 treatment could be a game changer.

Why Gilead Sciences Stock Is on Fire Today

Gilead Sciences Inc. GILD, +2.55% shares rallied in the extended session Thursday following a report that one of the company's drugs showed promising results in treating COVID-19 patients.

Gilead stock surges more than 10% on report of promising coronavirus treatment

The ETF tracking the S&P 500 rallied after hours after a report said a Gilead drug was showing effectiveness in treating the coronavirus.

S&P 500 ETF jumps 2% after hours on report Gilead drug showing effectiveness treating coronavirus

Gilead Sciences shares popped by more than 16% in after-hours trading Thursday after details leaked of a closely watched clinical trial of the company’s antiviral drug Remdesivir, showing what appears to be promising results in treating Covid-19.

Gilead stock surges after report says coronavirus drug trial shows encouraging early results

A Chicago hospital treating severe Covid-19 patients with Gilead Sciences' antiviral medicine remdesivir in a closely watched clinical trial is seeing rapid recoveries in fever and respiratory symptoms, with nearly all patients discharged in less than a week, STAT has learned.

Early peek at data on Gilead coronavirus drug suggests patients are responding to treatment

Arcus Biosciences

The two companies are apparently discussing either an equity purchase or some other form of cooperation.

Report: Gilead Is Considering Taking a Stake in Arcus Biosciences

Gilead (GILD) declines after a study on investigational antiviral, remdesivir, was suspended in China due to the lack of eligible patients.

Gilead Down on Suspension of Coronavirus Study in China

New information on this potential treatment for COVID-19 gives hope for a solution to the pandemic.

Gilead Sciences’ Remdesivir Data Release Brings Much Needed Relief for Patients and Investors

Gilead Sciences, Inc. (NASDAQ: GILD) shares are trading lower on Wednesday, after trials of the company's potential coronavirus candidate Remdesivir were suspended in China due to low enrollment.

Why Gilead's Stock Is Trading Lower Today

The clinical trial's sponsors say that COVID-19 has been so well controlled in Hubei province that they couldn't enroll enough patients.

Chinese Researchers Suspend Trial of Experimental Coronavirus Treatment

Shares of Gilead Sciences Inc. GILD, -3.78% fell 4% in trading on Wednesday afternoon after Chinese authorities said they stopped recruiting for a remdesivir clinical trial in severely ill COVID-19 patients there.

Gilead's stock drops after China halts second remdesivir trial

GILD stock is rising on Gilead's potential coronavirus cure. But Gilead also has a questionable past, and it faces worrying patent disputes.

Buying Gilead Sciences Stock Means Buying Into Political Risk

GILD stock is getting a boost from early trials of its remdesivir drug, which is showing some promise in treating the novel coronavirus.
The post Initial Coronavirus Treatment Trials Look Good for Gilead Stock appeared first on InvestorPlace.

Initial Coronavirus Treatment Trials Look Good for Gilead Stock

Gilead Sciences stock tripped Wednesday after Chinese researchers scrapped a second test of coronavirus treatment, remdesivir, due to low enrollment. The test was in moderate patients.

Covid Report: Gilead Trips After Coronavirus Drug Test Scrapped In China

Gilead delivered some good news on a remdesivir trial, That's positive news for GILD stock and the owners of the shares.
The post Gilead Stock Has Become a Coronavirus Star appeared first on InvestorPlace.

Gilead Stock Has Become a Coronavirus Star

Gilead Sciences: Analyzing Remdesivir's Potential In A Difficult Time

Gilead Sciences (GILD) has ignited a ray of hope with its recently-released positive data on the role of remdesivir as a COVID-19 treatment.

News for Gilead Sciences Stock (GILD)